Health Tech Capitol | Gregor Diagnostics seeking to upgrade prostate cancer screening
15960
post-template-default,single,single-post,postid-15960,single-format-standard,tribe-no-js,tribe-bar-is-disabled,ajax_fade,page_not_loaded,,qode-child-theme-ver-1.0.0,qode-theme-ver-9.3,wpb-js-composer js-comp-ver-4.12,vc_responsive

Gregor Diagnostics seeking to upgrade prostate cancer screening

26 Sep Gregor Diagnostics seeking to upgrade prostate cancer screening

Posted at 11:45h in Uncategorized by
0 Likes

A Wisconsin biotech company aiming to improve prostate cancer screening is seeking seed funds while competing in a startup accelerator in Texas.

Gregor Diagnostics was founded in February 2016 by CEO Tobias Zutz, who had worked for Exact Sciences for over five years before branching out on his own. After going through gener8tor’s gbeta program last summer, the company recently entered into a license agreement with WARF.

This agreement covers certain biomarkers which Gregor Diagnostics plans to develop and commercialize for a screening test for prostate cancer. The test would be an upgrade from the commonly used PSA blood test, Zutz says.

PSA stands for prostate specific antigen, a substance made by cells in the prostate gland.

Read more at WisBusiness

No Comments

Sorry, the comment form is closed at this time.